Cidara Therapeutics, Inc. (CDTX): History, Ownership, Mission, How It Works & Makes Money

Ever wonder about the companies behind cutting-edge immunotherapies? Is Cidara Therapeutics, Inc. (CDTX) one of them? This blog post dives into the world of Cidara Therapeutics, a biotechnology company focused on developing targeted immunotherapies, and as of December 31, 2024, the company reported a trailing 12-month revenue of $1.27 million. From its history and mission to its innovative Cloudbreak platform and how it generates revenue, we'll explore everything you need to know about this San Diego-based company, whose market capitalization stands at $199 million as of April 2025, and whose recent achievements include completing enrollment of its Phase 2b NAVIGATE trial and closing a $105 million financing round.

Cidara Therapeutics, Inc. (CDTX) History

Cidara Therapeutics, Inc. Founding Timeline

Year established

Cidara Therapeutics was founded in 2012.

Original location

The company is based in San Diego, California.

Founding team members

While specific names of all founding team members are not widely publicized, the establishment and early leadership included individuals with expertise in anti-infective drug development and commercialization.

Initial capital/funding

Cidara Therapeutics secured an initial Series A funding of $32 million in 2012, led by Frazier Healthcare Ventures.

Cidara Therapeutics, Inc. Evolution Milestones

Cidara Therapeutics, Inc. Transformative Moments

• Focus on Rezafungin Development: A key transformative decision was prioritizing the development of rezafungin, a novel echinocandin antifungal, targeting serious fungal infections. This strategic focus shaped the company’s clinical and regulatory pathway.
• Strategic Partnerships: Collaborating with Mundipharma to commercialize rezafungin in key global markets significantly de-risked the program and provided substantial financial resources.
• Navigating Regulatory Milestones: Successfully achieving FDA approval for rezafungin marked a pivotal moment, validating the company's research and development efforts and paving the way for commercialization.
• Acquisition by Melinta Therapeutics: The acquisition by Melinta Therapeutics represented a transformative moment, integrating Cidara's assets and expertise into a larger, more diversified anti-infectives company.

To gain more insights into the company's financial standing, consider exploring this resource: Breaking Down Cidara Therapeutics, Inc. (CDTX) Financial Health: Key Insights for Investors

Cidara Therapeutics, Inc. (CDTX) Ownership Structure

Cidara Therapeutics, Inc. operates as a public company, meaning its shares are available for trading on a stock exchange. This structure allows a broad range of investors to own a portion of the company, from individual shareholders to large institutional investors.

Cidara Therapeutics, Inc.'s Current Status

As a public company, Cidara Therapeutics, Inc. is subject to regulations and reporting requirements, providing transparency into its financial performance and operations. The company's stock ticker symbol is CDTX.

Cidara Therapeutics, Inc.'s Ownership Breakdown

Cidara Therapeutics, Inc. has a mix of institutional, retail, and insider ownership. As of 2024, the ownership is broken down as follows:

Cidara Therapeutics, Inc.'s Leadership

The leadership team guides the strategic direction and operational execution of Cidara Therapeutics, Inc.

• Jeffrey Stein, Ph.D., is the President and Chief Executive Officer
• Taylor Sandison, M.D., is the Chief Medical Officer

For insights into the company's goals and principles, explore: Mission Statement, Vision, & Core Values of Cidara Therapeutics, Inc. (CDTX).

Cidara Therapeutics, Inc. (CDTX) Mission and Values

Cidara Therapeutics is dedicated to developing innovative therapies that address unmet needs in infectious disease treatment. The company's mission is rooted in improving patient outcomes through the discovery, development, and commercialization of novel anti-infectives.

Cidara Therapeutics' Core Purpose

Official mission statement

While Cidara Therapeutics doesn't have a single, publicly declared official mission statement, its core purpose can be inferred from its activities and focus. Their activities include:

• Developing novel anti-infectives: Cidara focuses on creating new drugs to combat infections, addressing a critical need in healthcare.
• Addressing unmet needs: The company targets infectious diseases where current treatments are inadequate, aiming to provide better solutions for patients.
• Improving patient outcomes: Cidara's ultimate goal is to enhance the health and well-being of patients suffering from severe infections.

Vision statement

Again, while a specific vision statement isn't formally published, Cidara Therapeutics' vision can be understood through its strategic goals and long-term aspirations:

• Becoming a leader in anti-infective therapies: Cidara aims to be at the forefront of developing innovative treatments for infectious diseases.
• Expanding treatment options: The company seeks to broaden the range of available therapies for serious and life-threatening infections.
• Creating value through innovation: Cidara is committed to driving growth and delivering value by developing and commercializing novel products.

Company slogan/tagline

Cidara Therapeutics does not have an official slogan or tagline. However, considering their focus, a fitting tagline might emphasize their commitment to innovation and patient care in the realm of infectious diseases.

To gain a deeper understanding of the company's financial stability and long-term prospects, explore Breaking Down Cidara Therapeutics, Inc. (CDTX) Financial Health: Key Insights for Investors.

Cidara Therapeutics, Inc. (CDTX) How It Works

Cidara Therapeutics, Inc. is a biotechnology company focused on the development of novel anti-infectives designed to improve the lives of patients facing serious diseases. The company develops therapies that address unmet needs in fungal and viral infections.

Cidara Therapeutics, Inc. Product/Service Portfolio

Cidara Therapeutics, Inc. Operational Framework

Cidara Therapeutics operates with a focused approach to address significant gaps in the treatment of infectious diseases. The company's operations can be summarized as follows:

• Research and Development: Cidara focuses on discovering, developing, and commercializing innovative anti-infective therapies.
• Clinical Trials: A significant portion of their operations involves conducting clinical trials to evaluate the safety and efficacy of their product candidates.
• Regulatory Approval: They work closely with regulatory agencies like the FDA to gain approval for their drugs, which is a critical step in bringing their products to market.
• Partnerships and Collaborations: Cidara collaborates with other pharmaceutical companies and research institutions to expand their capabilities and resources. For instance, they have a licensing agreement with Melinta Therapeutics for the commercialization of rezafungin.

More insights can be found here: Breaking Down Cidara Therapeutics, Inc. (CDTX) Financial Health: Key Insights for Investors

Cidara Therapeutics, Inc. Strategic Advantages

Cidara Therapeutics, Inc. has several strategic advantages that enable its success in the competitive biopharmaceutical industry:

• Novel Technology: Cidara's expertise in developing innovative anti-infective therapies provides a competitive edge. Rezafungin, exemplifies this, offering a unique approach to treating life-threatening fungal infections.
• Strategic Partnerships: Collaborations enhance Cidara's capabilities, providing access to resources, funding, and expertise. The licensing agreement with Melinta Therapeutics for rezafungin is a prime example.
• Addressing Unmet Needs: By focusing on severe fungal and viral infections, Cidara targets markets with limited treatment options.

Cidara Therapeutics, Inc. (CDTX) How It Makes Money

Cidara Therapeutics, Inc. primarily focuses on the discovery, development, and commercialization of novel anti-infectives. The company generates revenue through strategic collaborations, licensing agreements, and, potentially in the future, through direct sales of its approved products.

Cidara Therapeutics, Inc. Revenue Breakdown

As a clinical-stage company, the majority of Cidara's revenue has historically come from collaborations and licensing agreements rather than product sales. Given the dynamic nature of the pharmaceutical industry and the stage of Cidara's pipeline, specific percentages may fluctuate significantly year to year.

Cidara Therapeutics, Inc. Business Economics

The business economics of Cidara are influenced by several factors:

• R&D Investment: A significant portion of expenses is allocated to research and development, particularly for advancing its antifungal and antiviral therapies.
• Partnerships: Strategic alliances are crucial for funding and expertise, affecting both revenue and cost structures.
• Clinical Trial Success: Positive clinical trial outcomes can substantially increase the company's valuation and attract further investment.
• Regulatory Approvals: FDA and other regulatory approvals are critical milestones that enable product commercialization and revenue generation.

Cidara Therapeutics, Inc. Financial Performance

Key aspects of Cidara's financial performance include:

• Revenue: Revenues are largely dependent on collaboration agreements and milestone payments.
• Operating Expenses: Consist primarily of R&D and general administrative costs.
• Cash Runway: Monitoring cash reserves is vital, as the company relies on financing activities to fund operations until product revenues materialize.
• Net Loss: As a development-stage company, Cidara typically experiences net losses, which are expected to decrease upon successful commercialization of its products.

For more detailed insights into Cidara Therapeutics, Inc.'s financial health, you can explore: Breaking Down Cidara Therapeutics, Inc. (CDTX) Financial Health: Key Insights for Investors

Cidara Therapeutics, Inc. (CDTX) Market Position & Future Outlook

Cidara Therapeutics is navigating a challenging financial landscape, as highlighted by its recent strategic moves to extend its cash runway and focus on core programs. Its future success hinges on the clinical development and potential commercialization of its antifungal and antiviral therapies. To gain a better understanding of investor sentiment and activity surrounding the company, check out: Exploring Cidara Therapeutics, Inc. (CDTX) Investor Profile: Who’s Buying and Why?

Competitive Landscape

Note: Market share data for antifungal therapeutics can fluctuate based on specific drug approvals, regional sales, and evolving treatment guidelines. Exact market share percentages for each company are difficult to ascertain without access to proprietary market research data.

Opportunities & Challenges

Industry Position

Cidara Therapeutics is a clinical-stage biotechnology company focused on developing novel anti-infectives. Here are some key aspects of its industry position:

• Specialized Focus: Cidara concentrates on addressing unmet needs in the treatment of fungal and viral infections, a space where antibiotic resistance is a growing concern.
• Innovative Technology: The company's Cloudbreak platform aims to create targeted therapies that improve patient outcomes.
• Strategic Realignment: Recent corporate updates indicate a focus on extending its cash runway and prioritizing core programs, which suggests a strategic effort to maximize resources and focus on high-potential assets.